-
公开(公告)号:US20160060324A1
公开(公告)日:2016-03-03
申请号:US14786419
申请日:2014-04-18
IPC分类号: C07K14/755 , A61K38/37 , A61K47/48
CPC分类号: C07K14/755 , A61K38/00 , A61K38/37 , A61K47/6425
摘要: The present invention provides immune conjugates for inducing antigen specific immune tolerance to coagulation Factor VIII. The immune conjugates contain a FVIII protein or antigenic fragment that is conjugated to a binding moiety for a sialic acid binding Ig-like lectin (Siglec) expressed on B cells. The invention also provides methods of using the FVIII immune conjugates to induce immune tolerance to FVIII in a subject. Additionally provided in the invention are methods for treating bleeding disorders such as hemophilia A via the use of the FVIII immune conjugates and an unconjugated FVIII with coagulating activity.
摘要翻译: 本发明提供用于诱导对凝血因子VIII的抗原特异性免疫耐受性的免疫结合物。 免疫缀合物含有与B细胞上表达的唾液酸结合Ig样凝集素(Siglec)的结合部分缀合的FVIII蛋白或抗原性片段。 本发明还提供使用FVIII免疫缀合物诱导受试者对FVIII的免疫耐受的方法。 本发明另外提供的是通过使用FVIII免疫缀合物和具有凝结活性的非共轭FVIII来治疗出血性疾病如血友病A的方法。
-
公开(公告)号:US09522183B2
公开(公告)日:2016-12-20
申请号:US13261580
申请日:2011-07-29
IPC分类号: A61K39/385 , A61K9/127 , A61K39/00 , A61K39/35 , A61K47/48
CPC分类号: A61K39/0008 , A61K9/127 , A61K39/001 , A61K39/35 , A61K39/385 , A61K47/6911 , A61K2039/5154 , A61K2039/5158 , A61K2039/55555
摘要: The present invention provides liposomal compositions for inducing immune tolerance. The compounds typically comprise a liposome displaying a specific antigen and also a binding moiety for a sialic acid binding Ig-like lectin (Siglec)expressed on B cells. The invention also provides methods for inducing tolerance to a protein or polypeptide antigen (e.g., a protein antigen) in a subject. The methods involve administering to the subject a pharmaceutical composition that co-presents both the antigen and a glycan ligand for a Siglec expressed on B lymphocytes.
摘要翻译: 本发明提供用于诱导免疫耐受的脂质体组合物。 化合物通常包含显示特异性抗原的脂质体,以及用于在B细胞上表达的唾液酸结合Ig样凝集素(Siglec)的结合部分。 本发明还提供了诱导受试者中蛋白质或多肽抗原(例如,蛋白质抗原)的耐受性的方法。 所述方法包括对受试者施用共同呈递在B淋巴细胞上表达的Siglec的抗原和聚糖配体的药物组合物。
-
公开(公告)号:US20230037822A1
公开(公告)日:2023-02-09
申请号:US17755382
申请日:2020-10-28
发明人: James C. Paulson , Maidul Islam , Fabian Pfrengle , Matthew Macauley , Shiteng Duan , Britni Arlian
摘要: Described herein are Siglec ligand-antibody conjugates and compositions thereof that are useful for suppressing unwanted immune responses such as allergies and anaphylaxis.
-
公开(公告)号:US20120316207A1
公开(公告)日:2012-12-13
申请号:US13591927
申请日:2012-08-22
申请人: David Vocadlo , Ernest McEachern , Keith Stubbs , Tong-Shuang Li , Garrett Whitworth , Julia Heinonen , Matthew Macauley
发明人: David Vocadlo , Ernest McEachern , Keith Stubbs , Tong-Shuang Li , Garrett Whitworth , Julia Heinonen , Matthew Macauley
IPC分类号: A61K31/429 , C07D513/04
CPC分类号: G01N33/6803 , C07D513/04 , C07D513/14 , C07F9/6561 , C07H9/06
摘要: The invention provides compounds of formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
摘要翻译: 本发明提供了用于选择性抑制糖苷酶,化合物前药和包括化合物的化合物或前药的药物组合物的式(I)化合物。 本发明还提供了治疗与O-GlcNAcase的缺乏或过度表达相关的疾病和障碍的方法,O-GlcNAc的积累或缺乏。
-
公开(公告)号:US08334310B2
公开(公告)日:2012-12-18
申请号:US12438882
申请日:2007-08-31
申请人: David Vocadlo , Ernest McEachern , Keith Stubbs , Tong-Shuang Li , Garrett Whitworth , Julia Heinonen , Matthew Macauley
发明人: David Vocadlo , Ernest McEachern , Keith Stubbs , Tong-Shuang Li , Garrett Whitworth , Julia Heinonen , Matthew Macauley
IPC分类号: A61K31/429 , C07D513/04
CPC分类号: G01N33/6803 , C07D513/04 , C07D513/14 , C07F9/6561 , C07H9/06
摘要: The invention provides compounds of formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc
摘要翻译: 本发明提供了用于选择性抑制糖苷酶,化合物前药和包含化合物或药物前体药物的药物组合物的式(I)化合物。本发明还提供了治疗与O-GlcNAcase的缺乏或过度表达有关的疾病和病症的方法, O-GlcNAc的积累或不足
-
公开(公告)号:US08962664B2
公开(公告)日:2015-02-24
申请号:US13591927
申请日:2012-08-22
申请人: David Vocadlo , Ernest McEachern , Keith Stubbs , Tong-Shuang Li , Garrett Whitworth , Julia Heinonen , Matthew Macauley
发明人: David Vocadlo , Ernest McEachern , Keith Stubbs , Tong-Shuang Li , Garrett Whitworth , Julia Heinonen , Matthew Macauley
IPC分类号: A61K31/429 , C07D513/04 , G01N33/68 , C07D513/14 , C07F9/6561 , C07H9/06
CPC分类号: G01N33/6803 , C07D513/04 , C07D513/14 , C07F9/6561 , C07H9/06
摘要: The invention provides compounds of formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
摘要翻译: 本发明提供了用于选择性抑制糖苷酶,化合物前药和包括化合物的化合物或前药的药物组合物的式(I)化合物。 本发明还提供了治疗与O-GlcNAcase的缺乏或过度表达相关的疾病和障碍的方法,O-GlcNAc的积累或缺乏。
-
公开(公告)号:US20100016386A1
公开(公告)日:2010-01-21
申请号:US12438882
申请日:2007-08-31
申请人: David Vocadlo , Ernest McFachern , Keith Stubbs , Tong-Shuang Li , Garrett Whitworth , Julia Heinonen , Matthew Macauley
发明人: David Vocadlo , Ernest McFachern , Keith Stubbs , Tong-Shuang Li , Garrett Whitworth , Julia Heinonen , Matthew Macauley
IPC分类号: A61K31/429 , C07D513/02 , C12Q1/34 , A61P25/00 , A61P35/00 , A61P29/00 , A61P37/08 , A61P11/00 , A61P37/06
CPC分类号: G01N33/6803 , C07D513/04 , C07D513/14 , C07F9/6561 , C07H9/06
摘要: The invention provides compounds of formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc
摘要翻译: 本发明提供了用于选择性抑制糖苷酶,化合物前药和包含化合物或药物前体药物的药物组合物的式(I)化合物。本发明还提供了治疗与O-GlcNAcase的缺乏或过度表达有关的疾病和病症的方法, O-GlcNAc的积累或不足
-
-
-
-
-
-